Scientists at La Jolla Institute for Immunology and Scripps Research have developed a novel HIV vaccine that has shown unprecedented success in preclinical studies, eliciting the best HIV-fighting antibody response ever seen in primates.

This groundbreaking vaccine works by training the immune system to produce rare "broadly neutralizing" antibodies, which are crucial for combating HIV's defenses. After 14 years of collaboration, the research, published in Nature, marks a significant step in the quest for an effective HIV vaccine. The vaccine guides B cells, which produce antibodies, from their naive state to a mature, virus-fighting form, overcoming HIV's ability to evade the immune system.

The vaccine's approach, termed "germline targeting," was tested in rhesus macaques, with approximately 44 percent of the animals producing the desired broadly neutralizing antibodies. This success in primates, led by researchers like Shane Crotty, Ph.D., and William Schief, Ph.D., has led to the initiation of human trials, offering new hope in the fight against HIV/AIDS.